Drug Discovery

Electronic laboratory notebook (ELN)
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Chemical engineering #Chemistry #Computational chemistry #Drug development #High Content Screening #Mass spectrometry / NMR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Sequencing #System biology #Systems biology #Target validation

Enterprise ELNs as a Foundation for Preclinical Drug Development

Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More

#Archive

#Analysis #Biochemistry #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #PCR #Pharmacology #RNA #Stem cells

New Trends and Therapeutic Approaches for the Management of Diabetic Retinopathy

New Trends and Therapeutic Approaches for the Management of Diabetic Retinopathy By Dr Didier Pruneau Diabetes mellitus is a growing epidemic that has become a global public health problem. The long-term complications of diabetes include retinopathy, the leading cause of blindness and visual impairment in adults. Diabetic retinopathy correlates with… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #Toxicology

3D Cell Culture: Easier said than done

3D Cell Culture: Easier said than done By Dr John Comley The transition from cell culture on the flat surface of a conventional two-dimensional (2D) culture vessel to a three-dimensional (3D) environment, matrix or scaffold with 3D architecture has begun, and is providing much needed support for emerging applications in… Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Biomarkers #Business #Drug development #Drug discovery #Genetics / genomes #Genomics #High throughput screening #Imaging #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Target validation #Therapeutics #Toxicology

Personalised Medicine Market and Regulatory Landscape

Personalised Medicine Market and Regulatory Landscape By Dr Enal Razvi and Dr Patricia Hurley Over the past several years, there has been continuing interest in the deployment of personalised medicine via the development of companion diagnostics/therapeutics. The leading edge of this discipline is in the cancer personalised medicine arena where… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Tracking HTS Assay Development Time: Opportunity for improving drug discovery

Tracking HTS Assay Development Time: Opportunity for improving drug discovery By Dr Jennifer Hartigan, Cindy Liu and William Downey High throughput screening (HTS) assays are developed more quickly now due to advances in technology, improved liquid handling and sensitive detection, as well as increased communication between scientists in high throughput… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #RNA #Screening #Stem cells #Target validation

Fluorescence Lifetime: Finally picking up momentum!

Fluorescence Lifetime: Finally picking up momentum! By Dr John Comley Fluorescence lifetime (FLT) largely failed to make a significant inroad as a screening technology when it was first introduced nearly a decade ago, despite the fact that intrinsically it has many benefits, particularly in dealing with assay interferences. Market studies… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Overview of Companion Diagnostics in the Pharmaceutical Industry Part 2: Business models

Overview of Companion Diagnostics in the Pharmaceutical Industry Part 2: Business models. By Dr Stephen Naylor and Toby Cole There is an emerging consensus that the development of Companion Diagnostics appears to offer a set of tools to address many of the current problems that pharmaceutical companies must overcome. This in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Molecular medicine #Regenerative Medicine #Screening #Stem cells #Therapeutics #Toxicology

Stem Cells for Cellular Therapy Space

Stem Cells for Cellular Therapy Space By Dr Enal S. Razvi and Dr Gary M. Oosta This article explores the emerging market landscape vis--vis the use of stem cells as cellular therapeutics. For more than 40 years, hematopoietic stem cells have been utilised as cellular therapeutics in a number of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Metabolomics #Molecular medicine #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Target validation #Toxicology #Translational #Translational chemistry

Towards Unbiased Biomarker Discovery

Towards Unbiased Biomarker Discovery Dr Jens Hoefkens High-throughput molecular profiling technologies are routinely applied for biomarker discovery to make the drug discovery process more efficient and enable personalised medicine. The ability to find novel biomarkers rests on large-scale data generation and unbiased data analysis. Over the past decade, biomarker discovery… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Immunology #Oncology #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Recent Advances in HCS Laser Scanning Cytometry

By Dr John Comley Laser scanning cytometers have matured over the past decade to meet the needs of end-users for higher throughput cell analysis, to access to previously difficult applications and to keep pace with the diversity of new fluorophores, validated high content screening (HCS) assay kits and reagents now… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #PCR #Screening #Toxicology

Compound Profiling: Size impact on primary screening libraries

By William Downey, Cindy Liu and Dr Jennifer Hartigan A recent report examines the trends in utilisation of compound libraries, as well as the impact of profiling on the size of screening decks. The drivers for choosing between large or focused libraries may be different, but the ultimate goal remains… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #Lead discovery #Lead optimisation #Microfluidics #PCR #RNA #Stem cells #Target validation #Theranostics

Real-Time PCR – Where we are and where are we heading

By Dr Mikael Kubista Quantitative real-time PCR is becoming mature technology for the quantification of nucleic acids. It is spreading wide outside its original use in the research laboratories, becoming preferred technology for a range of applications, many that require specialised so lutions and adaptations. Integration with pre-analytical steps and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Utilising 3D nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening

Utilising 3D nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening By Professor Jian Tajbakhsh, Professor Arkadiusz Gertych and Professor Daniel L Farkas Since epigenetic changes are thought to underlie a wide range of complex diseases, the scope of epigenetic drug therapy is likely to expand, as epigenetic… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #RNA #Sequencing #System biology #Systems biology #Translational #Translational chemistry

The Healthcare Industry’s Evolving Role in Translational Research an Opportunity for Competitive Advantage

The Healthcare Industry's Evolving Role in Translational Research an Opportunity for Competitive Advantage By Gregory Venters During the 20th century, medical research has observed enormous advances in basic science discovery, highlighted by the sequencing of the human genome. However, we have not witnessed a corresponding success in the widespread application… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Systems biology #Theranostics #Therapeutics #Toxicology

Overview of Companion Diagnostics in the Pharmaceutical Industry: Part 1

By Dr Stephen Naylor and Toby Cole In this article we describe the current state of Companion Diagnostics and its impact on the pharmaceutical sector, and the need for Companion Diagnostics in the drug discovery and development process. This perspective is augmented by a consideration of the development of Companion… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Regulatory #RNA #Screening #System biology #Systems biology #Target validation

Design Of Experiments: Useful statistical tool in assay development or vendor disconnect

Design Of Experiments: Useful statistical tool in assay development or vendor disconnect By Dr John Comley The use of design of experiments (DOE) in assay development (AD) has the potential to speed up assay optimisation (ie reduce assay development bottlenecks) and to facilitate a more thorough evaluation of assay variables. Read More

#Archive